Creo Medical Group (CREO)

Sector:

Health Care

Index:

FTSE AIM All-Share

16.13p
   
  • Change Today:
    -0.13p
  • 52 Week High: 48.10
  • 52 Week Low: 15.70
  • Currency: UK Pounds
  • Shares Issued: 412.15m
  • Volume: 519,832
  • Market Cap: £66.46m
  • Beta: 0.20

Creo Medical's 'Speedboat Inject' used for first time in Europe

By Josh White

Date: Monday 26 Jun 2023

LONDON (ShareCast) - (Sharecast News) - Surgical endoscopy specialist Creo Medical announced on Monday that Dr Adolfo Parra-Blanco at Nottingham University Hospital NHS Trust had become the first clinician to perform an upper gastrointestinal (GI) tract 'Speedboat Inject' case in Europe, since clearance was gained last week.
The AIM-traded firm said the procedure saw a seven-by-five centimetre cancerous lesion in the stomach removed in one piece in less than two hours.

It said it was performed after Dr Parra-Blanco led an upper GI endoscopy education and training day at the University of Nottingham, where familiarised himself with the Speedboat Inject device for use in the upper GI tract.

The result of the procedure was described as "excellent", with the patient leaving hospital shortly after.

A second doctor was now also trained to use Speedboat Inject for upper GI procedures at Nottingham, and Nottingham University Hospital NHS Trust-led Upper GI ESD courses showcasing Speedboat were set to take place next week and in August at Queens Medical Centre in Nottingham.

Creo said it would continue to work closely with Nottingham University Hospital NHS Trust to support the training, mentoring and adoption of the device by numerous upper GI specialists over the coming months.

That, it said, would be in conjunction with Creo's Pioneer training programme, with the company expecting a rapid adoption of the device for upper GI procedures over the coming months.

"To have the first case completed at such a well-respected and prestigious endoscopic centre, renowned for its upper GI services, so soon after clearance demonstrates both the appetite for the device to be used in the upper GI tract in Europe and the ability for clinicians to quickly get optimal results once they are familiar with the advanced energy," said chief executive officer Craig Gulliford.

"We look forward to continuing to work with Nottingham University Hospital NHS Trust and others to maximise the roll out of the device in the entire GI tract."

At 1024 BST, shares in Creo Medical Group were up 9.06% at 36.7p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CREO Market Data

Currency UK Pounds
Share Price 16.13p
Change Today -0.13p
% Change -0.77 %
52 Week High 48.10
52 Week Low 15.70
Volume 519,832
Shares Issued 412.15m
Market Cap £66.46m
Beta 0.20

CREO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
10.11% above the market average10.11% above the market average10.11% above the market average10.11% above the market average10.11% above the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average
Price Trend
84.58% below the market average84.58% below the market average84.58% below the market average84.58% below the market average84.58% below the market average
51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average
Income Not Available
Growth
24.32% above the market average24.32% above the market average24.32% above the market average24.32% above the market average24.32% above the market average
55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CREO Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
16:20 20,343 @ 16.12p
16:10 3,206 @ 16.15p
14:56 234 @ 16.24p
14:45 19,868 @ 16.12p
13:59 38,584 @ 16.12p

CREO Key Personnel

CEO Craig Jonathan Gulliford
CFO Richard John Rees

Top of Page